Strategic Advocacy
The Strategic Advocacy division is comprised of several major policy divisions within the Chamber including theCyber, Space, and National Security Division; Economic Policy Division; Employment Policy Division; and Small Business Policy Division. Environmental Affairs and Sustainability, Health Policy, and Transportation and Infrastructure Policy are also under the umbrella of the Policy Group.
The division works closely with the Chamber's Congressional and Public Affairs and Political Affairs and Federation Relations divisions.
Latest Content
President Trump on June 19 announced his intent to nominate Marvin Kaplan of the Occupational Safety and Health Review Commission...
In today’s highly digitized and interconnected world, a simplified and reliable view of an organization’s cyber defenses can help immensely.
The U.S. Chamber of Commerce today announced that Alejandro Mayorkas has been selected to serve as Chairman of its Cyber Leadership Council. Mayorkas’ term will begin in July.
Members of the House Energy and Commerce and Senate Energy and Natural Resources Committees:
MetLife and the U.S. Chamber held its first Small Business Series in Dallas, Texas.
When the National Labor Relations Board (NLRB) issued the Browning-Ferris decision back in 2015, it established an expansive new...
As this blog has noted on many occasions, the Obama-era National Labor Relations Board (NLRB) was one of the more excessive regulators...
As readers of this blog know, the National Labor Relations Board (NLRB) issued a great number of slanted decisions during the Obama era. Unfortunately, that trend has continued under the current 2-1 Democrat majority, highlighted by a recent case RHCG Safety Corp. In it, the Board not only established yet another illogical and impractical precedent, but also exposed some of the flaws of the ambush election rule.
On June 7, DOL withdrew two Obama-era interpretive bulletins covering employee misclassification and the joint employer standard...
On Tuesday, June 6, 2017, this letter was sent to the members of the House Energy and Commerce Committee opposing any amendments that may be offered to H.R. 2430, the FDA Reauthorization Act (FDARA) of 2017, that would allow the importation of foreign pharmaceuticals into the United States or that would undermine the preemptive authority of federal food and drug regulations. The Committee will mark up the bill tomorrow morning. June 6, 2017 Dear Chairman Walden and Ranking Member Pallone: